한글목차

의약품 수탁판매 아웃소싱 시장 - 조사 범위

TMR의 조사 보고서 '세계의 의약품 수탁판매 아웃소싱 시장'은 2025-2035년 예측 기간 동안 시장 지표에 대한 가치 있는 인사이트를 얻기 위해 과거 및 현재의 성장 동향과 기회를 연구합니다. 2025년 기준 연도, 2035년 예측연도로 2025-2035년 세계의 의약품 수탁판매 아웃소싱 시장 수익과 예측을 제공합니다. 또한 2025-2035년 세계의 의약품 수탁판매 아웃소싱 시장 연평균 성장률(CAGR%)도 제공합니다.

본 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 KOL(Key Opinion Leader), 업계 리더, 의견 형성자들과 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 문서 등을 참조하여 의약품 수탁판매 아웃소싱 시장을 파악했습니다.

본 보고서는 세계의 의약품 수탁판매 아웃소싱 시장 경쟁 구도를 조사했습니다. 세계의 의약품 수탁판매 아웃소싱 시장에서 활동하는 주요 업체들을 식별하고, 각 업체를 다양한 속성 측면에서 프로파일링했습니다. 기업 개요, 재무 현황, 최근 동향, SWOT 분석은 본 보고서에서 프로파일링된 세계의의 의약품 수탁판매 아웃소싱 시장 참여 기업 속성입니다.

세계의 의약품 수탁판매 아웃소싱 시장 보고서에서 다루는 주요 질문

• 세계의 의약품 수탁판매 아웃소싱 시장에서 비즈니스 기회는 무엇인가?
• 시장의 주요 촉진요인, 시장 성장 억제요인, 기회, 위협은 무엇인가?
• 예측 기간 동안 가장 빠른 CAGR로 성장하는 지역 시장은 어디인가?
• 2035년 세계에서 가장 높은 수익을 올릴 것으로 예상되는 부문은 무엇인가?
• 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상되는 부문은 무엇인가?
• 세계 시장에서 활동하는 다양한 기업의 시장 포지션은 무엇인가?

의약품 수탁판매 아웃소싱 시장 - 조사 목적 및 조사 방법

본 조사 보고서는 세계의 의약품 수탁판매 아웃소싱 시장에 대해 연구 및 분석한 보고서입니다. 본 보고서는 연구 목적과 시장 내 주요 공급업체 및 유통업체, 제품 승인 관련 규제 환경에 대한 상세한 설명을 제공합니다.

독해 편의성을 위해 보고서는 장별 구성으로 편성되었으며, 각 부분은 소단위로 세분화되었습니다. 보고서는 적절히 배치된 방대한 그래프 및 표를 포함합니다. 주요 부문의 실제 및 예상 값을 시각적으로 표현한 내용은 독자에게 시각적 매력을 제공합니다. 이는 또한 과거와 예측 기간 말 시점의 주요 부문 시장 점유율 비교를 가능하게 합니다.

본 보고서는 전 세계의 의약품 수탁판매 아웃소싱 시장을 제품, 최종 사용자 및 지역별로 분석합니다. 각 기준의 주요 부문을 상세하게 조사하고 2035년 말 시점의 각 부문에 대한 시장 점유율을 제공합니다. 이러한 귀중한 인사이트로 시장 이해관계자는 전 세계의 의약품 수탁판매 아웃소싱 시장에 대한 투자에 대한 충분한 정보를 바탕으로 비즈니스 의사 결정을 내릴 수 있습니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 소개
• 개요
• 시장 역학
• 세계의 의약품 수탁판매 아웃소싱 시장 분석과 예측(2020-2035년)

제5장 주요 인사이트

• 주요 지역 및 국가의 의료비 지출
• 의약품 판매 아웃소싱의 장점
• Porter's Five Forces 분석
• PESTEL 분석
• 주요 업계 이벤트(파트너십, 콜라보레이션, 제품 승인, 합병 및 인수)

제6장 세계 시장 분석과 예측 : 서비스 유형별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 서비스 유형별(2020-2035년)
  • 개인 프로모션
    • 프로모션 영업팀
      • 전임 영업팀
      • 신디케이트 영업팀
    • 주요 고객 관리
    • 공석 관리
  • 비개인 프로모션
    • 텔레디테일링
    • 인터랙티브 E-디테일링
    • 고객 서비스
    • 의학 과학 연락 담당자
    • 환자 참여 서비스
    • 기타
  • 기타
• 시장의 매력 : 서비스 유형별

제7장 세계 시장 분석과 예측 : 치료 영역별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 치료 영역별(2020-2035년)
  • 심혈관 질환
  • 종양성 질환
  • 호흡기 질환
  • 대사 장애
  • 신경질환
  • 정형외과 질환
  • 감염증
  • 기타
• 시장의 매력 : 치료 영역별

제8장 세계 시장 분석과 예측 : 최종 사용자별

• 소개 및 정의
• 주요 조사 결과 및 진전
• 시장 매출 예측 : 최종 사용자별(2020-2035년)
  • 제약회사
    • 신약 개발사
    • 제네릭 의약품 개발 기업
    • 백신 개발사
  • 생명공학 기업
• 시장의 매력 : 최종 사용자별

제9장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 지역별 시장의 매력

제10장 북미 시장 분석과 예측

• 미국
• 캐나다

제11장 유럽 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 스위스
• 네덜란드
• 기타 유럽

제12장 아시아태평양 시장 분석과 예측

• 중국
• 인도
• 일본
• 한국
• 호주 및 뉴질랜드
• 기타 아시아태평양

제13장 라틴아메리카 시장 분석과 예측

• 브라질
• 멕시코
• 아르헨티나
• 기타 라틴아메리카

제14장 중동 및 아프리카 시장 분석과 예측

• GCC 국가
• 남아프리카
• 기타 중동 및 아프리카

제15장 경쟁 구도

• 시장 기업 : 경쟁 매트릭스(기업 등급별, 규모별)
• 시장 점유율 분석기업별(2024년)
• 기업 프로파일
  • IQVIA
  • Axxelus
  • EPS Corporation(EPS Holdings, Inc.)
  • Syneos Health
  • EVERSANA
  • CMIC HOLDINGS Co., LTD.
  • QFR Solutions
  • Sales Focus Inc.
  • GTS Solution
  • Mercalis
  • MaBiCo
  • Mednext Pharmaceuticals Pvt. Ltd.
  • Peak Pharma Solutions Inc.
  • Promoveo Health
  • Agilify Solutions Inc.

영문목차

Pharmaceutical Contract Sales Outsourcing Market- Scope of Report

TMR's report on the global Pharmaceutical Contract Sales Outsourcing Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Pharmaceutical Contract Sales Outsourcing Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Pharmaceutical Contract Sales Outsourcing Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Pharmaceutical Contract Sales Outsourcing Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Pharmaceutical Contract Sales Outsourcing Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Pharmaceutical Contract Sales Outsourcing Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Pharmaceutical Contract Sales Outsourcing Market .

The report delves into the competitive landscape of the global Pharmaceutical Contract Sales Outsourcing Market . Key players operating in the global Pharmaceutical Contract Sales Outsourcing Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Pharmaceutical Contract Sales Outsourcing Marketprofiled in this report.

Key Questions Answered in Global Pharmaceutical Contract Sales Outsourcing MarketReport:

• What are the opportunities in the global Pharmaceutical Contract Sales Outsourcing Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Pharmaceutical Contract Sales Outsourcing Market- Research Objectives and Research Approach

The comprehensive report on the global Pharmaceutical Contract Sales Outsourcing Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Pharmaceutical Contract Sales Outsourcing Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Pharmaceutical Contract Sales Outsourcing Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pharmaceutical Contract Sales Outsourcing Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Advantages of Pharmaceutical Sales Outsourcing
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTLE Analysis
• 5.5. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)

6. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Service Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Service Type, 2020 to 2035
  • 6.3.1. Personal Promotion
    • 6.3.1.1. Promotional Sales Team
      • 6.3.1.1.1. Dedicated Sales Team
      • 6.3.1.1.2. Syndicated Sales Team
    • 6.3.1.2. Key Account Management
    • 6.3.1.3. Vacancy Management
  • 6.3.2. Non-Personal Promotion
    • 6.3.2.1. Tele-detailing
    • 6.3.2.2. Interactive E-Detailing
    • 6.3.2.3. Customer Service
    • 6.3.2.4. Medical Science Liaisons
    • 6.3.2.5. Patient Engagement Services
    • 6.3.2.6. Others
  • 6.3.3. Others
• 6.4. Market Attractiveness By Service Type

7. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Therapeutic Area

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 7.3.1. Cardiovascular Disorders
  • 7.3.2. Oncological Disorders
  • 7.3.3. Respiratory Disorders
  • 7.3.4. Metabolic Disorders
  • 7.3.5. Neurological Disorders
  • 7.3.6. Orthopedic Disorders
  • 7.3.7. Infectious Diseases
  • 7.3.8. Others
• 7.4. Market Attractiveness By Therapeutic Area

8. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020 to 2035
  • 8.3.1. Pharmaceutical Companies
    • 8.3.1.1. Novel Drug Developers
    • 8.3.1.2. Generic Drug Developers
    • 8.3.1.3. Vaccine Developers
  • 8.3.2. Biotechnology Companies
• 8.4. Market Attractiveness By End-user

9. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Service Type, 2020 to 2035
  • 10.2.1. Personal Promotion
    • 10.2.1.1. Promotional Sales Team
      • 10.2.1.1.1. Dedicated Sales Team
      • 10.2.1.1.2. Syndicated Sales Team
    • 10.2.1.2. Key Account Management
    • 10.2.1.3. Vacancy Management
  • 10.2.2. Non-Personal Promotion
    • 10.2.2.1. Tele-detailing
    • 10.2.2.2. Interactive E-Detailing
    • 10.2.2.3. Customer Service
    • 10.2.2.4. Medical Science Liaisons
    • 10.2.2.5. Patient Engagement Services
    • 10.2.2.6. Others
  • 10.2.3. Others
• 10.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 10.3.1. Cardiovascular Disorders
  • 10.3.2. Oncological Disorders
  • 10.3.3. Respiratory Disorders
  • 10.3.4. Metabolic Disorders
  • 10.3.5. Neurological Disorders
  • 10.3.6. Orthopedic Disorders
  • 10.3.7. Infectious Diseases
  • 10.3.8. Others
• 10.4. Market Value Forecast By End-user, 2020 to 2035
  • 10.4.1. Pharmaceutical Companies
    • 10.4.1.1. Novel Drug Developers
    • 10.4.1.2. Generic Drug Developers
    • 10.4.1.3. Vaccine Developers
  • 10.4.2. Biotechnology Companies
• 10.5. Market Value Forecast By Country, 2020 to 2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Service Type
  • 10.6.2. By Therapeutic Area
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Service Type, 2020 to 2035
  • 11.2.1. Personal Promotion
    • 11.2.1.1. Promotional Sales Team
      • 11.2.1.1.1. Dedicated Sales Team
      • 11.2.1.1.2. Syndicated Sales Team
    • 11.2.1.2. Key Account Management
    • 11.2.1.3. Vacancy Management
  • 11.2.2. Non-Personal Promotion
    • 11.2.2.1. Tele-detailing
    • 11.2.2.2. Interactive E-Detailing
    • 11.2.2.3. Customer Service
    • 11.2.2.4. Medical Science Liaisons
    • 11.2.2.5. Patient Engagement Services
    • 11.2.2.6. Others
  • 11.2.3. Others
• 11.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 11.3.1. Cardiovascular Disorders
  • 11.3.2. Oncological Disorders
  • 11.3.3. Respiratory Disorders
  • 11.3.4. Metabolic Disorders
  • 11.3.5. Neurological Disorders
  • 11.3.6. Orthopedic Disorders
  • 11.3.7. Infectious Diseases
  • 11.3.8. Others
• 11.4. Market Value Forecast By End-user, 2020 to 2035
  • 11.4.1. Pharmaceutical Companies
    • 11.4.1.1. Novel Drug Developers
    • 11.4.1.2. Generic Drug Developers
    • 11.4.1.3. Vaccine Developers
  • 11.4.2. Biotechnology Companies
• 11.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Switzerland
  • 11.5.7. The Netherlands
  • 11.5.8. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Service Type
  • 11.6.2. By Therapeutic Area
  • 11.6.3. By End-user
  • 11.6.4. By Country / Sub-region

12. Asia Pacific Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Service Type, 2020 to 2035
  • 12.2.1. Personal Promotion
    • 12.2.1.1. Promotional Sales Team
      • 12.2.1.1.1. Dedicated Sales Team
      • 12.2.1.1.2. Syndicated Sales Team
    • 12.2.1.2. Key Account Management
    • 12.2.1.3. Vacancy Management
  • 12.2.2. Non-Personal Promotion
    • 12.2.2.1. Tele-detailing
    • 12.2.2.2. Interactive E-Detailing
    • 12.2.2.3. Customer Service
    • 12.2.2.4. Medical Science Liaisons
    • 12.2.2.5. Patient Engagement Services
    • 12.2.2.6. Others
  • 12.2.3. Others
• 12.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 12.3.1. Cardiovascular Disorders
  • 12.3.2. Oncological Disorders
  • 12.3.3. Respiratory Disorders
  • 12.3.4. Metabolic Disorders
  • 12.3.5. Neurological Disorders
  • 12.3.6. Orthopedic Disorders
  • 12.3.7. Infectious Diseases
  • 12.3.8. Others
• 12.4. Market Value Forecast By End-user, 2020 to 2035
  • 12.4.1. Pharmaceutical Companies
    • 12.4.1.1. Novel Drug Developers
    • 12.4.1.2. Generic Drug Developers
    • 12.4.1.3. Vaccine Developers
  • 12.4.2. Biotechnology Companies
• 12.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. South Korea
  • 12.5.5. Australia & New Zealand
  • 12.5.6. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Service Type
  • 12.6.2. By Therapeutic Area
  • 12.6.3. By End-user
  • 12.6.4. By Country / Sub-region

13. Latin America Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Service Type, 2020 to 2035
  • 13.2.1. Personal Promotion
    • 13.2.1.1. Promotional Sales Team
      • 13.2.1.1.1. Dedicated Sales Team
      • 13.2.1.1.2. Syndicated Sales Team
    • 13.2.1.2. Key Account Management
    • 13.2.1.3. Vacancy Management
  • 13.2.2. Non-Personal Promotion
    • 13.2.2.1. Tele-detailing
    • 13.2.2.2. Interactive E-Detailing
    • 13.2.2.3. Customer Service
    • 13.2.2.4. Medical Science Liaisons
    • 13.2.2.5. Patient Engagement Services
    • 13.2.2.6. Others
  • 13.2.3. Others
• 13.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 13.3.1. Cardiovascular Disorders
  • 13.3.2. Oncological Disorders
  • 13.3.3. Respiratory Disorders
  • 13.3.4. Metabolic Disorders
  • 13.3.5. Neurological Disorders
  • 13.3.6. Orthopedic Disorders
  • 13.3.7. Infectious Diseases
  • 13.3.8. Others
• 13.4. Market Value Forecast By End-user, 2020 to 2035
  • 13.4.1. Pharmaceutical Companies
    • 13.4.1.1. Novel Drug Developers
    • 13.4.1.2. Generic Drug Developers
    • 13.4.1.3. Vaccine Developers
  • 13.4.2. Biotechnology Companies
• 13.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Service Type
  • 13.6.2. By Therapeutic Area
  • 13.6.3. By End-user
  • 13.6.4. By Country / Sub-region

14. Middle East & Africa Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Service Type, 2020 to 2035
  • 14.2.1. Personal Promotion
    • 14.2.1.1. Promotional Sales Team
      • 14.2.1.1.1. Dedicated Sales Team
      • 14.2.1.1.2. Syndicated Sales Team
    • 14.2.1.2. Key Account Management
    • 14.2.1.3. Vacancy Management
  • 14.2.2. Non-Personal Promotion
    • 14.2.2.1. Tele-detailing
    • 14.2.2.2. Interactive E-Detailing
    • 14.2.2.3. Customer Service
    • 14.2.2.4. Medical Science Liaisons
    • 14.2.2.5. Patient Engagement Services
    • 14.2.2.6. Others
  • 14.2.3. Others
• 14.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 14.3.1. Cardiovascular Disorders
  • 14.3.2. Oncological Disorders
  • 14.3.3. Respiratory Disorders
  • 14.3.4. Metabolic Disorders
  • 14.3.5. Neurological Disorders
  • 14.3.6. Orthopedic Disorders
  • 14.3.7. Infectious Diseases
  • 14.3.8. Others
• 14.4. Market Value Forecast By End-user, 2020 to 2035
  • 14.4.1. Pharmaceutical Companies
    • 14.4.1.1. Novel Drug Developers
    • 14.4.1.2. Generic Drug Developers
    • 14.4.1.3. Vaccine Developers
  • 14.4.2. Biotechnology Companies
• 14.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Service Type
  • 14.6.2. By Therapeutic Area
  • 14.6.3. By End-user
  • 14.6.4. By Country / Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. IQVIA
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Axxelus
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. EPS Corporation (EPS Holdings, Inc.)
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Syneos Health
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. EVERSANA
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. CMIC HOLDINGS Co., LTD.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. QFR Solutions
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Sales Focus Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. GTS Solution
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Mercalis
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. MaBiCo
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Mednext Pharmaceuticals Pvt. Ltd.
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Product Portfolio
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Peak Pharma Solutions Inc.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Product Portfolio
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments
  • 15.3.14. Promoveo Health
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Product Portfolio
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Developments
  • 15.3.15. Agilify Solutions Inc.
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Financial Overview
    • 15.3.15.3. Product Portfolio
    • 15.3.15.4. Business Strategies
    • 15.3.15.5. Recent Developments